Pfizer’s Strategic Shift Weighs on Investor Sentiment

Pfizer Inc. used the prominent J.P. Morgan Healthcare Conference to detail its future roadmap, but the market’s response has been tepid. The pharmaceutical giant’s ambitious pivot is coming at a clear cost to near-term earnings, as evidenced by a 2026 profit forecast that fell short of Wall Street’s expectations.

While the company reaffirmed its guidance for the current year, its inaugural projection for 2026 proved to be a letdown for investors. Pfizer anticipates an adjusted earnings per share of between $2.80 and $3.00 for that period. This range sits notably below the analyst consensus estimate of $3.05. The primary drivers of this gap are significant research and development expenditures. The recent $10 billion acquisition Read more...